NeOnc’s Insider Buying Spurs Hope: Breakthrough Glioma Data & $15 M Funding Poised for FDA Break
NeOnc’s insider buy‑in and $15M raise after 48.9% PFS in Phase 2a NEO100 could signal a breakthrough in IDH1‑mutant glioma—investors weigh high risk, high reward.
4 minutes to read
